Chemistry: analytical and immunological testing – Lipids – triglycerides – cholesterol – or lipoproteins
Reexamination Certificate
2007-07-31
2007-07-31
Wallenhorst, Maureen M. (Department: 1743)
Chemistry: analytical and immunological testing
Lipids, triglycerides, cholesterol, or lipoproteins
C436S161000, C436S164000, C436S172000, C436S173000, C422S070000, C422S082050, C422S082080, C435S011000
Reexamination Certificate
active
11053123
ABSTRACT:
This invention provides novel assays that are prognostic and/or diagnostic for atherosclerosis or risk of atherosclerosis. It was discovered that high density lipoprotein (HDL) or components thereof can prevent the oxidation of lipids (e.g., lipids present in LDLs) and can also repair (reduce) already oxidized lipids and thereby reduce the inflammatory response associated with and characteristic of atherosclerotic plaque formation. Moreover it was a discovery of this invention that individuals vary in the ability of their HDL to afford such protection. Thus an assay of HDL protective and/or repair activity provides a highly effective assay for risk of atherosclerosis and its associated pathologies and such assays are provided herein.
REFERENCES:
patent: 4367285 (1983-01-01), Yamaguchi et al.
patent: H930 (1991-06-01), Kato et al.
patent: 5118601 (1992-06-01), Gruber
patent: 5135716 (1992-08-01), Thakore
patent: 5231090 (1993-07-01), Hsia et al.
patent: 5458896 (1995-10-01), Porter
patent: 5561052 (1996-10-01), Koike
patent: 5989803 (1999-11-01), Tabas et al.
patent: 6074834 (2000-06-01), Slezak et al.
patent: 6265147 (2001-07-01), Mobley et al.
patent: 6299858 (2001-10-01), Serbedzija et al.
patent: 6309888 (2001-10-01), Holvoet et al.
patent: 6362236 (2002-03-01), Aviram et al.
patent: 6596544 (2003-07-01), Fogelman et al.
patent: 6869568 (2005-03-01), Fogelman et al.
patent: WO 1994/023302 (1994-10-01), None
patent: WO 1996/018898 (1996-06-01), None
patent: 97/36927 (1997-09-01), None
patent: 98/20897 (1998-05-01), None
patent: WO 1998/059248 (1998-12-01), None
patent: 99/47566 (1999-09-01), None
Navab et al. Journal of Lipid Research, vol. 42, 2001, pp. 1308-1317.
Anderson et al. (1987) “Cholesterol and Mortality: 30 Years of Follow-up From the Framingham Study.”Journal of the American Medical Association, 257: 2176-2180.
Badimon et al. (1989), “High Density Lipoprotein Plasma Fractions Inhibit Aortic Fatty Streaks in Cholesterol-Fed Rabbits.”Laboratory Investigation, 60:455-461.
Barr et al. (1951) “Protein-Lipid Relationships in Human Plasma: II. In Atherosclerosis and Related Conditions.”The American Journal of Medicine, 11:480-493.
Bruce et al. (1998), “Plasma Lipid Transfer Proteins, High-Density Lipoproteins, and Reverse Cholesterol Transport.”Annual Review of Nutrition, 18:297-330.
Chisolm (1991), “Antioxidants and Atherosclerosis: A Current Assessment.”Clinical Cardiology, 14:125-130.
Christison et al. (1995), “Exchange of oxidized cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer protein.”Journal of Lipid Research, 36:2017-2026.
Cyrus et al. (1999), “Disruption of the 12/15-lipooxygenase gene diminishes atherosclerosis in apo E-deficientmice.”The Journal of Clinical Investigation, 103: 1487-1488.
Fluiter et al. (1999) “Scavenger Receptor BI Mediates the Selective Uptake of Oxidized Cholesterol Esters by Rat Liver.”Journal of Biological Chemistry, 274:8893-8899.
Forte et al. (1995) “Recruitment of cell phospholipids and cholesterol by apolipoprotein-specific HDL that differ in size, phospholipid composition, and reactivity with LCAT.”Journal of Lipid Research36:148-157.
Garner et al. (1998) “Oxidation of High Density Lipoproteins: Formation of Methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by ∝-Tocopherol.”Journal of Biological Chemistry, 273:6080-6087.
Garner et al. (1998) “Oxidation of High Density of Lipoproteins: Evidence for Direct Reduction of Lipid Hydroperoxides by Methionine Residues of Apolipoproteins AI and AII.”Journal of Biological Chemistry, 273:6088-6095.
Gofman et al. (1966) “Ischemic Heart Disease, Atherosclerosis, and Longevity.”Circulation, 34:679-697.
Gordon et al. (1989), “High-Density Lipoprotein Cholesterol and Cardiovascular Disease: Four Prospective American Studies.”Circulation, 79:8-15.
Hama (1997), “Apolipoprotein A-I Can Remove Lipid Molecules from Native LDL Rendering it Resistant to Oxidation by Cultured Artery Wall Cells.”Circulation, 96:I-485, Abst.
Hama et al. (1998), “Circulating Low Density Lipoprotein-Minus Induces Marked Monocyte-endothelial Interactions.”Circulation, 98:I-252, Abst.
Laplaud et al. (1998) “Paraoxonase as risk marker for cardovascular disease: Facts and Hypothesis”Clin. Chem and Lab Med. vol. 36, No. 7, pp. 431-441.
Mackness et al. (1995) “HDL, its enzymes and its potential to influence lipid peroxidation”Atheroschlerosis, 115, pp. 243-253.
Mackness et al. (1999) “Low serum paraoxonase: a risk factor for atherosclerotic disease?”Chem-Biol Inter, 119-120, pp. 389-397.
Metzler et al. (1999) Database BIOSIS on STN. “LDL stimulates mitogen-activated protein kinase phosphatase-1 expression, independent of LDL receptors, in vascular smooth muscle cells.”Arteriosclerosis, Thrombosis, and Vasular Biology, 19(8): 1862-1871.
Miller and Miller (1975) “Plasma-High-Density-Lipoprotein Concentration and Development of Ischæmic Heart-Disease.”Lancet, 1:16-19.
Navab et al. (1991) “Monocyte Transmigration Induced by Modification of Low Density Lipoprotein in Cocultures of Human Aortic Wall Cells Is due to Induction of Monocyte Chemotactic Protein 1 Synthesis and Is Abolished by High Density Lipoprotein,”The Journal of Clinical Investigation, 88:2039-2046.
Navab et al. (1997) “Mildly Oxidized LDL Induces an Increased ApolipoproteinJ/Paraoxonase Ratio.”The Journal of Clinical Investigation, 99: 2005-2019.
Navab et al. (2002) “Oxidized Lipids as Mediators of Coronary Heart Disease.”Current Opinion in Lipidology, 13(4): 363-372.
Oram and Yokoyama (1996) “Apolipoprotein-mediated removal of cellular cholesterol and phospholids.”Journal of Lipid Research, 37:2473-2491.
Parthasarathy (1994), In:Free Radicals in the Enviornment, Medicine and Toxicology, pp. 163-179. H. Nohl, H. Esterbauer, and C. Rice Evans, eds. Richelieu Press, London.
Parthasarathy (1994), “Mechanisms of Oxidation of LDL,” pp. 91-119. In:Modified Lipoproteins in the Pathogenesis of Atherosclerosis, R.G. Landes Co., Austin, TX.
Phillips et al. (1998) “Mechanisms of high density lipoprotein-mediated efflux of cholesterol from cell plasma membranes.”Atheroscler, 137 Supp: S13-S17.
Polidori et al. (1998) “Increased Plasma Levels of Lipid Hydroperoxides in Patients with Ischemic Stroke.”Free Rad. Biol. Med., 25:561-567.
Sevanian et al. (1997) “LDL is a lipid Hydroperoxide-enriched circulating lipoprotein.”Journal of Lipid Research, 38:419-428.
Shwaery et al. (1999) “Preparation of Lipid Hydroperoxide-Free Low Density Lipo-proteins.”Meth. Enz., 300:17-23.
Sigari et al. (1997) “Fibroblasts That Overexpress 15-Lipoxygenase Generate Bioactive and Minimally Modified LDL.”Arteriosclerosis, Thrombosis and Vascular Biology, 17:3639-3645.
Stampfer et al. (1991) “A Prospective Study of Cholesterol, Apolipoproteins, and the risk of mycocardial infarction.”The New England Journal of Medicine, 325:373-381.
Thomas and Jackson (1991) “Lipid Hydroperoxide Involvement in Copper-Dependent and Independent Oxidation of Low Density Lipoproteins.”The Journal of Pharmacology and Experimental Therapeutics, 256:1182-1188.
Thomas et al. (1994) “Involvement of Pre-existing Lipid Hydroperoxides in Cu2+-Stimulated Oxidation of Low-Density Lipoproteind1.”Archives of Biochemistry and Biophysics, 315:244-254.
Van de Vijver et al. (1998) “LDL oxidation and extent of coronary atherosclerosis”Arteriosclerosis, Thrombosis and Vascular Biology, 18: 193-199.
Vega and Grundy (1996) “Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease.”Current Opinion in Lipidology,
Fogelman Alan M
Hama Susan
Navab Mohamad
Beyer & Weaver, LLP
Hunter Tom
The Regents of the University of California
Wallenhorst Maureen M.
LandOfFree
Functional assay of high-density lipoprotein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Functional assay of high-density lipoprotein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Functional assay of high-density lipoprotein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3794598